The discovery of the scientists allowed the rapid development of antiviral drugs directed at hepatitis C.

As the development of virus-specific vaccines and antiviral drugs usually take a great deal of time, broad-spectrum antiviral drugs could b...

Researchers from Johannes Gutenberg University Mainz (JGU) in Germany simulated the way that about 42,000 different substances listed in op...

Natco Pharma launched fixed dose combination of Sofosbuvir-Daclatasvir tablets for the treatment of Hepatitis C under the brand name Hepcin...

Between 130 and 150 million people worldwide are estimated to have HCV. The vast majority lives in low and middle income countries, it adde...

The drug called Epclusa which is developed to treat all genotypes of the Hepatitis C virus by Gilead Sciences in its latest breakthrough tr...

Scientists have for the first time found that it is possible to generate simultaneous immune response against Hepatitis C virus and HIV, ra...

Daclatasvir, discovered and developed by Bristol-Myer Squibb, is the first-in-class NS5A inhibitor used in combination with Sofosbuvir to t...

Cipla has launched generic tablets used for treating of hepatitis C under the brand name 'Hepcvir-L' costing Rs 25,000 for a bottle of 28 t...

During the conference, two new drugs were launched for treatment of Hepatitis C disease at affordable price.

Daclatasvir in combination with Sofosbuvir is indicated for the treatment of Hepatitis C genotype 3 infections, which is highly prevalent i...

Natco Pharma has got approval from the Drugs Controller General of India (DCGI) to sell generic version of Daclatasvir, which is used for t...

People infected with HIV are already known to have an elevated risk for heart disease but hepatitis C can spark cardiovascular damage indep...

Hepatitis C virus causes chronic infection leading to cirrhosis and may cause liver cancer.

"India is facing a serious threat from Hepatitis C virus (HCV). It is, however, going to take a lot more than low-cost drugs to get patient...

The voluntary licencing deal promises to make the drug cheap in India as well as up to 91 countries where the Indian firms are allowed to s...

The findings can bring an effective hepatitis C vaccine closer to reality.